Navigation Links
New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs
Date:2/14/2012

cessary to determine if angiogenesis-blocking drugs are particularly effective in patients with the angiogenic subtype. But there is reason for optimism: about 30 percent of serous ovarian cancer patients who receive angiogenesis inhibitors in a clinical trial benefit from the drugs; and the angiogenic subtype comprises about 30 percent of all serous ovarian cancers. "It is a test like this that may in the future help us select which patients will benefit most from a drug like Avastin," says Matulonis.

The researchers believe that their classification of this new subtype has great potential to influence the treatment many patients receive and improve outcomes for a significant number of people with this disease. "The approach we've taken in this study offers a powerful way of identifying molecular subtypes of other cancers as well," says Quackenbush.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes
2. GW researchers reveal 18 novel subtype-dependent genetic variants for autism spectrum disorders and identify potential genetic markers for diagnostic screening
3. Different origins discovered for medulloblastoma tumor subtypes
4. Decreased survival for Puerto Rican women with triple-negative breast cancer subtype
5. New subtype of breast cancer responds to targeted drug
6. Faulty proteins may prove significant in identifying new treatments for ovarian cancer
7. Fat cells in abdomen fuel spread of ovarian cancer
8. Purdue technology used in first fluorescence-guided ovarian cancer surgery
9. Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds
10. Low dose naltrexone (LDN): Harnessing the bodys own chemistry to treat human ovarian cancer
11. University of Houston researcher an author of multi-institutional genetic study of ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... spring weather in 2010 and 2012 resulted in the earliest ... two sites in the eastern US, according to research published ... by Elizabeth Ellwood of Boston University and colleagues. ... changes that make them bloom in the spring. According to ...
... and Barry Magee from Queen,s School of Biological Sciences ... small electrical shocks, and their behaviour after experiencing those ... Journal of Experimental Biology ., Professor Elwood,s previous research ... way consistent with pain. This latest study provides further ...
... is increasing from multiple scientific fields that exposure to the ... by the U.S. Forest Service, the presence of trees was ... forester at the Forest Service,s Pacific Northwest Research Station, and ... eastern and midwestern United States was an unprecedented opportunity to ...
Cached Biology News:'Shell-shocked' crabs can feel pain 2Tree and human health may be linked 2
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... A study published online today in Genome Research ... evolutionary conservation of the genes and pathways associated with ... aging-related genes in simple model organisms that may lead ... in human aging and age-associated diseases. , While nearly ...
... (Nasdaq: EXEL ) announced today that George A. ... present at the,Cowen and Company Annual Health Care Conference ... March 17, 2008. Dr. Scangos will discuss updates to ... will be webcast and may be accessed in the ...
... March 12 UCT Specialties LLC is now,offering their ... years of,experience in research and development and with input ... for many years, each guide is,designed to illustrate and ... the products it represents., With thousands of calls ...
Cached Biology Technology:Growing old together: Yeast, worms and people may age by similar mechanisms 2UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings 2
... includes 2 tube gel adaptors, 24 ... length), gaskets, grommets, stoppers. The PROTEAN II ... cell offer the versatility to perform a ... second-dimension 2-D electrophoresis, native, preparative, and gradient ...
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
... The PROTEAN II XL cell, wide format, is used ... x 20 cm gels and requires 1.2 L of ... unit and the 2.0 mm IPG conversion kit, which ... and includes 2 sets of IPG clamps, 2 sets ...
... depletion cocktail is tailored to ... suspensions of rat spleen cells. ... StemSep (or compatible 0.5 Tesla) ... T cell content of the ...
Biology Products: